The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire

Patel, Amit; Siegert, Richard J.; Brignall, Katherine; Gordon, Patrick; Steer, Sophia; Desai, Sujal R.; Maher, Toby M.; Renzoni, Elisabetta A.; Wells, Athol U.; Higginson, Irene J; Birring, Surinder S.

doi:10.1136/thoraxjnl-2012-201581

Cited by 202 publications

(253 citation statements)

References 19 publications

(16 reference statements)

Supporting

Mentioning

237

Contrasting

Unclassified

Order By: Relevance

“…Other available questionnaires are the Tool to Assess Quality of Life in Idiopathic Fibrosis (ATAQ-IPF) [38]. The SGRQ-I, which is an IPF-specific version of the SGRQ [19], and King’s Brief Interstitial Lung Disease (K-BILD) questionnaire [39] also exist. However, they have not been independently validated and are not widely used, and the K-BILD does not include questions about cough, a cardinal symptom in IPF patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Validation of the COPD Assessment Test (CAT) in patients with idiopathic pulmonary fibrosis

Grufstedt

Shaker

Konradsen

2018

European Clinical Respiratory Journal

View full text Add to dashboard Cite

Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic disease with high morbidity and mortality. A reliable and manageable questionnaire that assesses patients’ quality of life is needed to help to improve the content of clinical consultations. The chronic obstructive pulmonary disease (COPD) Assessment Test (CAT) is used in clinical practice; therefore, the aim of this study was to investigate correlations among the CAT, St. George’s Respiratory Questionnaire (SGRQ) and clinical parameters among patients diagnosed with IPF.Methods: A retrospective cohort design was employed in which 87 patients diagnosed with IPF who were receiving treatment at an outpatient clinic were included.Results: The CAT was found to be significantly correlated with SGRQ (p < 0.001). Furthermore, the CAT was significantly correlated with all of the included physiological variables.Conclusions: This add to support the validity of the COPD Assessment test (CAT) as a measure of symptoms in patients with IPF which in clinical practice in combination with dialogue between healthcare professionals and the patient, can help to improve the content of a clinical consultation.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, whereas it was originally a COPD questionnaire, we chose the CAT for the aforementioned reasons. In fact, the CAT includes items that are valuable for assessing IPF, including fatigue and sleep quality, which are not available in disease-specific questionnaires [39]. …”

Section: Discussionmentioning

confidence: 99%

Validation of the COPD Assessment Test (CAT) in patients with idiopathic pulmonary fibrosis

Grufstedt

Shaker

Konradsen

2018

European Clinical Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…Recordings were centrally analysed with automated cough software as previously described [7]. On the days of cough recording, participants completed the Leicester Cough Questionnaire (LCQ, a cough-specific health status questionnaire), the VAS cough severity, VAS urge-to-cough, King's Brief Interstitial Lung Disease health status questionnaire (K-BILD), the Hospital Anxiety and Depression Scale (HADS) and the seven-item Generalised Anxiety Disorder screener (GAD-7) [8,9].Analyses were performed on the intention-to-treat population. Objective cough frequency data were log transformed.…”

mentioning

confidence: 99%

Effect of Pirfenidone on cough in patients with Idiopathic Pulmonary Fibrosis

et al. 2017

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease. In patients with IPF, cough is one of the most disabling symptoms and is an independent predictor of disease progression [1][2][3]. Cough in IPF is often non-responsive to antitussive therapy [4], and studies on cough are scarce and have unfortunately not yet resulted in effective treatments. Several observations suggest that pirfenidone, an anti-fibrotic drug, might decrease cough [5, 6]. We aimed to measure objectively the effect of pirfenidone on cough in patients with IPF and substantial cough. In addition, we assessed the effect of pirfenidone on subjective cough and quality of life (QoL) measures.This international, multicentre, prospective, observational study at four sites (The Netherlands, Italy, France and UK) recruited patients between 2013 and 2016. Treatment-naïve IPF patients aged 40-85 years with a forced vital capacity (FVC) ⩾50% and corrected transfer factor of the lung for carbon monoxide (TLCOc) ⩾30%, in whom pirfenidone therapy was about to be initiated according to regular practice, who had daily IPF-related cough for ⩾8 weeks with a cough score of ⩾40 mm on a 0-100 mm visual analogue scale (VAS), were eligible for the present study.Patients underwent baseline 24-h cough recording with the Leicester Cough Monitor (LCM) prior to starting pirfenidone, and after 4 and 12 weeks of treatment. The LCM is a validated ambulatory cough monitoring system [7]. Recordings were centrally analysed with automated cough software as previously described [7]. On the days of cough recording, participants completed the Leicester Cough Questionnaire (LCQ, a cough-specific health status questionnaire), the VAS cough severity, VAS urge-to-cough, King's Brief Interstitial Lung Disease health status questionnaire (K-BILD), the Hospital Anxiety and Depression Scale (HADS) and the seven-item Generalised Anxiety Disorder screener (GAD-7) [8,9].Analyses were performed on the intention-to-treat population. Objective cough frequency data were log transformed. To assess the effect of pirfenidone on cough over time we used a linear mixed model, which accounts for missing data [10]. Sensitivity analyses were performed on the per protocol population with a linear mixed model and paired t-tests. SPSS Statistics version 21.0 and R version 3.2.2 software packages were used for statistical analysis. The study was approved by the ethics committees of all participating centres (clinical trials.gov, NCT02009293). All patients provided written informed consent.Of the 46 patients screened for the study, 43 patients were included. Reasons for exclusion were low TLCOc and/or VAS scores. 38 patients completed 4 weeks of the study, and 31 completed 12 weeks. Reasons for dropout included: cessation of pirfenidone because of adverse events (8), logistic reasons (2), change of proton pomp inhibitor (1) and death (1). The age of the patients was 72±7 (mean±SD); most were men (33, 77%) and former smokers (34, 79%). Baseline cough counts, questionnaire scores and pulmonar...

show abstract

“…Studies reporting HRQoL in people with IPF were eligible for inclusion if they used either generic preference-based measures or the SGRQ, which is a disease-specific instrument used in IPF. Other recently developed disease-specific instruments such as the St George's Respiratory Questionnaire IPF (SGRQ-I), 106 the 'A Tool to Assess QOL in IPF' (ATAQ-IPF) 107 and the King's Brief Interstitial Lung Disease (K-BILD) 108 measures were not eligible for inclusion as there are currently no methods to map results of these to utility measures required for economic evaluation. Data from any study designs were eligible for inclusion in the systematic review.…”

Section: Systematic Review Of Health-related Quality Of Life Studiesmentioning

confidence: 99%

“…This does not appear to have been used in trials to date. Other disease-specific instruments such as the ATAQ-IPF 107 and the K-BILD 108 have also recently been developed.…”

Section: Dyspnoeamentioning

confidence: 99%

The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation

Loveman

Copley

Colquitt

et al. 2015

Health Technology Assessment

View full text Add to dashboard Cite

BackgroundIdiopathic pulmonary fibrosis (IPF) is a life-limiting lung disease that generally affects people over 60 years old. The main symptoms are shortness of breath and cough, and as the disease progresses there is a considerable impact on day-to-day life. Few treatments are currently available.ObjectivesTo conduct a systematic review of clinical effectiveness and an analysis of cost-effectiveness of treatments for IPF based on an economic model informed by systematic reviews of cost-effectiveness and quality of life.Data sourcesEleven electronic bibliographic databases, including MEDLINE, EMBASE, Web of Science, and The Cochrane Library and the Centre for Reviews and Dissemination databases, were searched from database inception to July 2013. Reference lists of relevant publications were also checked and experts consulted.MethodsTwo reviewers independently screened references for the systematic reviews, extracted and checked data from the included studies and appraised their risk of bias. An advisory group was consulted about the choice of interventions until consensus was reached about eligibility. A narrative review with meta-analysis was undertaken, and a network meta-analysis (NMA) was performed. A decision-analytic Markov model was developed to estimate cost-effectiveness of pharmacological treatments for IPF. Parameter values were obtained from NMA and systematic reviews. Univariate and probabilistic sensitivity analyses were undertaken. The model perspective is NHS and Personal Social Services, and discount rate is 3.5% for costs and health benefits.ResultsFourteen studies were included in the review of clinical effectiveness, of which one evaluated azathioprine, threeN-acetylcysteine (NAC) (alone or in combination), four pirfenidone, one BIBF 1120, one sildenafil, one thalidomide, two pulmonary rehabilitation, and one a disease management programme. Study quality was generally good, with a low risk of bias. The current evidence suggests that some treatments appear to be clinically effective. The model base-case results show increased survival for five pharmacological treatments, compared with best supportive care, at increased cost. General recommendations cannot be made of their cost-effectiveness owing to limitations in the evidence base.LimitationsFew direct comparisons of treatments were identified. An indirect comparison through a NMA was performed; however, caution is recommended in the interpretation of these results. In relation to the economic model, there is an assumption that pharmacological treatments have a constant effect on the relative rate of per cent predicted forced vital capacity decline.ConclusionsFew interventions have any statistically significant effect on IPF and a lack of studies on palliative care approaches was identified. Research is required into the effects of symptom control interventions, in particular pulmonary rehabilitation and thalidomide. Other research priorities include a well-conducted randomised controlled trial on inhaled NAC therapy and an updated evidence synthesis once the results of ongoing studies are reported.Study registrationThis study is registered as PROSPERO CRD42012002116.FundingThe National Institute for Health Research Health Technology Assessment programme.

show abstract

The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire

Cited by 202 publications

References 19 publications

Validation of the COPD Assessment Test (CAT) in patients with idiopathic pulmonary fibrosis

Validation of the COPD Assessment Test (CAT) in patients with idiopathic pulmonary fibrosis

Effect of Pirfenidone on cough in patients with Idiopathic Pulmonary Fibrosis

The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation

Contact Info

Product

Resources

About